Targeting Multiple Myeloma
Learn how rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma
![[wpbb post:title]](https://isoplexis.com/wp-content/uploads/2020/03/Webinar-Website-Covers-4.30-05.png)
Andrea Schmidts, Postdoctoral Research Fellow, MD Cellular Immunotherapy Program, MGH Cancer Center and Harvard Medical School
Discover how a trimeric extracellular moiety of APRIL has enhanced binding to BCMA and TACI compared with monomeric APRIL when incorporated into a CAR
Explore why trimeric APRIL-based CAR are efficient against BCMA-negative multiple myeloma
Learn why T cells transduced with a trimeric APRIL-based CAR are a promising approach for the treatment of multiple myeloma
